2024 World Conference on Lung Cancer (WCLC) - Posters-P1.13A.11 Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study

P1.13A.11 Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study

Back to course

Pdf Summary

The document provides an exploratory analysis on patterns of progressive disease (PD) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with a combination of atezolizumab and chemotherapy. This analysis is based on the IMfirst study, which aims to reflect real-world clinical practice in Spain, following the initial findings from prior studies such as IMpower133 and IMbrella A.<br /><br />The study differentiates between patients who had a long-term benefit (LTB) from the treatment, surviving beyond 24 months, and those who did not (no-LTB). Out of 155 enrolled patients, 118 experienced PD, with detailed reports available for 115. Results indicated that 73.9% of patients had PD in existing lesions, 59.1% in new lesions, with some overlaps.<br /><br />The outcomes showed that No-LTB patients were more prone to experiencing PD in existing lesions with a broader range of affected sites compared to LTB patients. New central nervous system (CNS) lesions were mainly observed in patients who did not receive prophylactic cranial irradiation (PCI). <br /><br />In terms of disease progression, existing lesions commonly recurred in the lungs, lymph nodes, and liver for no-LTB patients, whereas for LTB patients, they were prevalent in the lungs, lymph nodes, and pleura. New lesions appeared primarily in the CNS, lymph nodes, liver, and lungs for no-LTB patients and in the CNS, lungs, lymph nodes, and adrenal glands for LTB patients.<br /><br />The conclusions emphasize the need for further studies to validate these findings due to the limited sample size, suggesting potential areas for intervention and management of PD in ES-SCLC. The study was presented at the 2024 World Conference on Lung Cancer, and was supported by Roche Farma S.A.

Asset Subtitle

Rosario García-Campelo

Meta Tag

Speaker Rosario García-Campelo

Topic SCLC & Neuroendocrine Tumors

Keywords

extensive-stage small-cell lung cancer

atezolizumab

chemotherapy

IMfirst study

progressive disease

long-term benefit

prophylactic cranial irradiation

central nervous system lesions

disease progression

World Conference on Lung Cancer